{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T17:09:15Z","timestamp":1758042555484,"version":"3.44.0"},"reference-count":51,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:00:00Z","timestamp":1757548800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Sepsis is a severe systemic infection that can result in organ dysfunction and mortality. Dyslipidemia emerges as a key player in the intricate web of sepsis pathogenesis. Yet, the causal relationship between blood lipid profiles and sepsis risk remains uncertain. This study aims to investigate the association between genetically predicted lipid traits, drug targets, and sepsis.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>The UK Biobank\u2019s Genome-wide association studies (GWAS) produced data on lipid and apolipoprotein characteristics. Four independent GWAS datasets were used to generate the sepsis statistics. The study utilized the two-sample Mendelian randomization (MR) approach, which incorporates multivariable (MVMR) models, to assess the correlations between sepsis risk and lipid-related parameters. To gain further insight, expression quantitative trait loci (eQTL) data were used to investigate the significant drug targets for lipid-lowering.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Increasing ApoA-1 levels was associated with a diminished risk of sepsis (under 75) (OR 0.927, 95% CI 0.861\u20130.999; p\u2009=\u20090.047). This inverse correlation persevered even after performing multivariable MR. Elevated levels of HDL-C were associated with a decreased risk of sepsis (under 75) (OR 0.897, 95% CI 0.838\u20130.960; P\u2009=\u20090.002) and incidence of sepsis (OR 0.883, 95% CI 0.820\u20130.951; P\u2009=\u20090.001), which was consistent across sensitivity analyses. Furthermore, a decrease in total cholesterol exhibited a causal effect on sepsis in multivariable MR (OR 0.779, 95% CI 0.642\u20130.944; P\u2009=\u20090.01). The genetic variants related to lowering LDL-C, located near the HMGCR and LDLR genes, were predicted to elevate the risk of sepsis. Moreover, genetic mimicry near the ANGPTL3 and LPL gene suggested that reducing the activity of ANGPTL3 and LPL (mimicking antisense anti-ANGPTL3 and LPL agents) was forecasted to decrease sepsis risk.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Genetically inferred elevated ApoA-1, total cholesterol, and HDL-C manifest a protective effect against sepsis. Within the 9 lipid-lowering drug targets investigated ANGPTL3 and LPL exhibit potential as candidate drug targets for sepsis.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0331023","type":"journal-article","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:44:58Z","timestamp":1757612698000},"page":"e0331023","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Genetic association of lipids characteristics and lipid lowering drug target genes with sepsis"],"prefix":"10.1371","volume":"20","author":[{"given":"Yu","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiyue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuoran","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sujing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingchao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2121-9223","authenticated-orcid":true,"given":"Shubin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,9,11]]},"reference":[{"issue":"10219","key":"pone.0331023.ref001","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0140-6736(19)32989-7","article-title":"Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study","volume":"395","author":"SKE Rudd","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"pone.0331023.ref002","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1038\/s41467-017-02402-6","article-title":"The podoplanin-CLEC-2 axis inhibits inflammation in sepsis","volume":"8","author":"J Rayes","year":"2017","journal-title":"Nat Commun"},{"issue":"5","key":"pone.0331023.ref003","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1001\/jamainternmed.2020.0183","article-title":"Association of a Care Bundle for Early Sepsis Management With Mortality Among Patients With Hospital-Onset or Community-Onset Sepsis","volume":"180","author":"JD Baghdadi","year":"2020","journal-title":"JAMA Intern Med"},{"issue":"1","key":"pone.0331023.ref004","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13613-017-0284-3","article-title":"Low HDL levels in sepsis versus trauma patients in intensive care unit","volume":"7","author":"S Tanaka","year":"2017","journal-title":"Ann Intensive Care"},{"key":"pone.0331023.ref005","doi-asserted-by":"crossref","first-page":"103044","DOI":"10.1016\/j.ebiom.2020.103044","article-title":"Exploring the pathophysiology of post-sepsis syndrome to identify therapeutic opportunities","volume":"61","author":"EC van der Slikke","year":"2020","journal-title":"EBioMedicine"},{"issue":"4","key":"pone.0331023.ref006","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1093\/jac\/dkn019","article-title":"Statins for infection and sepsis: a systematic review of the clinical evidence","volume":"61","author":"ME Falagas","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"pone.0331023.ref007","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev-genom-083117-021731","article-title":"Inferring Causal Relationships Between Risk Factors and Outcomes from Genome-Wide Association Study Data","volume":"19","author":"S Burgess","year":"2018","journal-title":"Annu Rev Genomics Hum Genet"},{"issue":"9","key":"pone.0331023.ref008","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41576-018-0020-3","article-title":"Using genetic data to strengthen causal inference in observational research","volume":"19","author":"J-B Pingault","year":"2018","journal-title":"Nat Rev Genet"},{"issue":"16","key":"pone.0331023.ref009","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1001\/jama.2021.18236","article-title":"Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement","volume":"326","author":"VW Skrivankova","year":"2021","journal-title":"JAMA"},{"issue":"7726","key":"pone.0331023.ref010","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41586-018-0579-z","article-title":"The UK Biobank resource with deep phenotyping and genomic data","volume":"562","author":"C Bycroft","year":"2018","journal-title":"Nature"},{"issue":"11","key":"pone.0331023.ref011","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1038\/ng.2797","article-title":"Discovery and refinement of loci associated with lipid levels","volume":"45","author":"CJ Willer","year":"2013","journal-title":"Nat Genet"},{"issue":"1","key":"pone.0331023.ref012","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"F Mach","year":"2020","journal-title":"Eur Heart J"},{"issue":"25","key":"pone.0331023.ref013","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"SM Grundy","year":"2019","journal-title":"Circulation"},{"issue":"9","key":"pone.0331023.ref014","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41569-022-00676-y","article-title":"Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia","volume":"19","author":"J Bor\u00e9n","year":"2022","journal-title":"Nat Rev Cardiol"},{"issue":"9943","key":"pone.0331023.ref015","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0140-6736(14)61009-6","article-title":"LDL cholesterol: controversies and future therapeutic directions","volume":"384","author":"PM Ridker","year":"2014","journal-title":"Lancet"},{"issue":"4","key":"pone.0331023.ref016","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1161\/CIRCGENETICS.114.000952","article-title":"Effect of Bile Acid Sequestrants on the Risk of Cardiovascular Events: A Mendelian Randomization Analysis","volume":"8","author":"CARDIoGRAMplusC4D Consortium","year":"2015","journal-title":"Circ Cardiovasc Genet"},{"key":"pone.0331023.ref017","doi-asserted-by":"crossref","first-page":"186","DOI":"10.12688\/wellcomeopenres.15555.2","article-title":"Guidelines for performing Mendelian randomization investigations","volume":"28","author":"S Burgess","year":"2020","journal-title":"Wellcome Open Res"},{"key":"pone.0331023.ref018","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/ng.2795","article-title":"Common variants associated with plasma triglycerides and risk for coronary artery disease","volume":"45","author":"R Do","year":"2013","journal-title":"Nat Genet"},{"issue":"11","key":"pone.0331023.ref019","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1002\/sim.7221","article-title":"A framework for the investigation of pleiotropy in two-sample summary data Mendelian randomization","volume":"36","author":"J Bowden","year":"2017","journal-title":"Stat Med"},{"key":"pone.0331023.ref020","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.34408","article-title":"The MR-Base platform supports systematic causal inference across the human phenome","volume":"7","author":"G Hemani","year":"2018","journal-title":"Elife"},{"issue":"26","key":"pone.0331023.ref021","doi-asserted-by":"crossref","first-page":"5813","DOI":"10.1002\/sim.9156","article-title":"Pleiotropy robust methods for multivariable Mendelian randomization","volume":"40","author":"AJ Grant","year":"2021","journal-title":"Stat Med"},{"issue":"1","key":"pone.0331023.ref022","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13613-019-0541-8","article-title":"High-density lipoprotein (HDL) particle size and concentration changes in septic shock patients","volume":"9","author":"S Tanaka","year":"2019","journal-title":"Ann Intensive Care"},{"issue":"4","key":"pone.0331023.ref023","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s10238-015-0390-1","article-title":"Increased inflammatory markers with altered antioxidant status persist after clinical recovery from severe sepsis: a correlation with low HDL cholesterol and albumin","volume":"16","author":"L Vavrova","year":"2016","journal-title":"Clin Exp Med"},{"issue":"11","key":"pone.0331023.ref024","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1007\/s00134-009-1609-y","article-title":"Changes in HDL-associated apolipoproteins relate to mortality in human sepsis and correlate to monocyte and platelet activation","volume":"35","author":"S Barlage","year":"2009","journal-title":"Intensive Care Med"},{"key":"pone.0331023.ref025","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jcrc.2016.11.041","article-title":"Decreased high-density lipoprotein cholesterol level is an early prognostic marker for organ dysfunction and death in patients with suspected sepsis","volume":"38","author":"M Cirstea","year":"2017","journal-title":"J Crit Care"},{"issue":"5","key":"pone.0331023.ref026","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.jcrc.2014.04.018","article-title":"Serum lipid profile, cytokine production, and clinical outcome in patients with severe sepsis","volume":"29","author":"A Lekkou","year":"2014","journal-title":"J Crit Care"},{"key":"pone.0331023.ref027","first-page":"789298","article-title":"Prognostic Implications of Serum Lipid Metabolism over Time during Sepsis","volume":"2015","author":"SH Lee","year":"2015","journal-title":"Biomed Res Int"},{"issue":"2","key":"pone.0331023.ref028","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1161\/ATVBAHA.108.178681","article-title":"HDL remodeling during the acute phase response","volume":"29","author":"A Jahangiri","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"pone.0331023.ref029","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/ni.2784","article-title":"High-density lipoprotein mediates anti-inflammatory reprogramming of macrophages via the transcriptional regulator ATF3","volume":"15","author":"D De Nardo","year":"2014","journal-title":"Nat Immunol"},{"issue":"19","key":"pone.0331023.ref030","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1161\/CIRCULATIONAHA.110.961193","article-title":"High-density lipoprotein suppresses the type I interferon response, a family of potent antiviral immunoregulators, in macrophages challenged with lipopolysaccharide","volume":"122","author":"M Suzuki","year":"2010","journal-title":"Circulation"},{"issue":"3","key":"pone.0331023.ref031","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/imm.12638","article-title":"High-density lipoprotein reduces inflammation from cholesterol crystals by inhibiting inflammasome activation","volume":"149","author":"SG Thacker","year":"2016","journal-title":"Immunology"},{"issue":"2","key":"pone.0331023.ref032","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1128\/iai.28.2.373-380.1980","article-title":"Interaction of lipopolysaccharides with plasma high-density lipoprotein in rats","volume":"28","author":"MA Freudenberg","year":"1980","journal-title":"Infect Immun"},{"issue":"5","key":"pone.0331023.ref033","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1097\/01.CCM.0000059724.08290.51","article-title":"Lipoprotein metabolism in patients with severe sepsis","volume":"31","author":"HJ van Leeuwen","year":"2003","journal-title":"Crit Care Med"},{"issue":"1","key":"pone.0331023.ref034","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13613-017-0284-3","article-title":"Low HDL levels in sepsis versus trauma patients in intensive care unit","volume":"7","author":"S Tanaka","year":"2017","journal-title":"Ann Intensive Care"},{"issue":"11","key":"pone.0331023.ref035","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1007\/s00134-009-1609-y","article-title":"Changes in HDL-associated apolipoproteins relate to mortality in human sepsis and correlate to monocyte and platelet activation","volume":"35","author":"S Barlage","year":"2009","journal-title":"Intensive Care Med"},{"issue":"1","key":"pone.0331023.ref036","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1161\/ATVBAHA.119.313381","article-title":"Causal Inference for Genetically Determined Levels of High-Density Lipoprotein Cholesterol and Risk of Infectious Disease","volume":"40","author":"M Trinder","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"pone.0331023.ref037","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1097\/CCM.0000000000000165","article-title":"Low preoperative cholesterol level is a risk factor of sepsis and poor clinical outcome in patients undergoing cardiac surgery with cardiopulmonary bypass","volume":"42","author":"L Lagrost","year":"2014","journal-title":"Crit Care Med"},{"issue":"4","key":"pone.0331023.ref038","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1365-2362.2010.02269.x","article-title":"Lipoproteins and CETP levels as risk factors for severe sepsis in hospitalized patients","volume":"40","author":"CMC Grion","year":"2010","journal-title":"Eur J Clin Invest"},{"issue":"3","key":"pone.0331023.ref039","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jcrc.2015.01.001","article-title":"Decreased serum level of lipoprotein cholesterol is a poor prognostic factor for patients with severe community-acquired pneumonia that required intensive care unit admission","volume":"30","author":"Y-F Chien","year":"2015","journal-title":"J Crit Care"},{"issue":"1","key":"pone.0331023.ref040","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1186\/s13054-016-1579-8","article-title":"Cholesterol levels and long-term rates of community-acquired sepsis","volume":"20","author":"FW Guirgis","year":"2016","journal-title":"Crit Care"},{"issue":"1","key":"pone.0331023.ref041","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1186\/s12877-017-0685-z","article-title":"Serum total cholesterol and risk of cardiovascular and non-cardiovascular mortality in old age: a population-based study","volume":"17","author":"Y Liang","year":"2017","journal-title":"BMC Geriatr"},{"issue":"3","key":"pone.0331023.ref042","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/CCM.0000000000003551","article-title":"Low Low-Density Lipoprotein Levels Are Associated With, But Do Not Causally Contribute to, Increased Mortality in Sepsis","volume":"47","author":"KR Walley","year":"2019","journal-title":"Crit Care Med"},{"issue":"8","key":"pone.0331023.ref043","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1086\/323334","article-title":"The effect of statins on mortality in patients with bacteremia","volume":"33","author":"AP Liappis","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"7","key":"pone.0331023.ref044","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1161\/01.CIR.0000138932.17956.F1","article-title":"Prior statin therapy is associated with a decreased rate of severe sepsis","volume":"110","author":"Y Almog","year":"2004","journal-title":"Circulation"},{"issue":"21","key":"pone.0331023.ref045","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1161\/01.CIR.0000129774.09737.5B","article-title":"HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis","volume":"109","author":"MW Merx","year":"2004","journal-title":"Circulation"},{"issue":"1","key":"pone.0331023.ref046","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1161\/CIRCULATIONAHA.104.502195","article-title":"Statin treatment after onset of sepsis in a murine model improves survival","volume":"112","author":"MW Merx","year":"2005","journal-title":"Circulation"},{"issue":"9965","key":"pone.0331023.ref047","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0140-6736(14)61183-1","article-title":"HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials","volume":"385","author":"DI Swerdlow","year":"2015","journal-title":"Lancet"},{"issue":"258","key":"pone.0331023.ref048","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008782","article-title":"PCSK9 is a critical regulator of the innate immune response and septic shock outcome","volume":"6","author":"KR Walley","year":"2014","journal-title":"Sci Transl Med"},{"issue":"4","key":"pone.0331023.ref049","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/S0022-2275(20)32147-7","article-title":"Apolipoprotein E knock-out mice are highly susceptible to endotoxemia and Klebsiella pneumoniae infection","volume":"40","author":"N de Bont","year":"1999","journal-title":"J Lipid Res"},{"issue":"4","key":"pone.0331023.ref050","article-title":"Drug-target Mendelian randomisation applied to metabolic dysfunction-associated steatotic liver disease: opportunities and challenges","volume":"2","author":"S Luo","year":"2024","journal-title":"eGastroenterology"},{"issue":"3","key":"pone.0331023.ref051","first-page":"521","article-title":"Novel insights into causal effects of serum lipids and lipid-modifying targets on cholelithiasis","volume":"73","author":"L Chen","year":"2024","journal-title":"Gut"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0331023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:45:05Z","timestamp":1757612705000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0331023"}},"subtitle":[],"editor":[{"given":"J\u00e9r\u00f4me","family":"Robert","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,9,11]]},"references-count":51,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0331023","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2025,9,11]]}}}